Tegoprubart Momentum: A Tactical Long on Eledon as Transplant Immunosuppression Rewires the Market
Eledon Pharmaceuticals' anti-CD40L antibody tegoprubart (AT-1501) is showing meaningful clinical momentum as a potential alternative to calcineurin inhibitors in kidney transplantation. With positive Phase 2 BESTOW data, real-world use in a genetically modified pig kidney transplant, and a strengthened balance sheet from a $57.5M financing, ELDN lo…